Relationship between various clinical outcome assessments in patients with blepharospasm.
about
Upper facial chorea in Huntington diseaseDevelopment and validation of a clinical guideline for diagnosing blepharospasm.Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm.Pre-operative evaluations for DBS in dystonia.Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data.Dystonia rating scales: critique and recommendationsThe blink reflex recovery cycle differs between essential and presumed psychogenic blepharospasm.Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasmA new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteinsIn vivo confocal microscopy of meibomian glands in primary blepharospasm: A prospective case-control study in a Chinese population.Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial.Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasmDesigning clinical trials for dystonia.Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm.Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy.Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disordersBlepharospasm in children and adolescents.Blepharospasm 40 years later.Changes in corneal aesthesiometry and the sub-basal nerve plexus in benign essential blepharospasm.Pallidal stimulation for medically intractable blepharospasm.The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.Photophobia in primary headaches, in essential blepharospasm and in major depression.Early use of Xeomin neurotoxin for local anti-spasticity therapy for pes equines after acquired brain injury (ABI).Medical Cannabis, a Beneficial High in Treatment of Blepharospasm? An Early Observation.Altered functional connectivity in blepharospasm/orofacial dystonia.Isolated focal dystonia phenotypes are associated with distinct patterns of altered microstructureEvaluation of Scheimpflug imaging parameters in blepharospasm and normal eyes
P2860
Q27321026-8CA90194-CAC4-47D4-B6D0-1F65BA77AC65Q30544592-764E8969-4BEE-426C-A5A5-4490CB8ECA3AQ33935194-7D987E11-34DF-42F7-B4BB-C4AAFA590257Q33938316-42A3F5E2-FA4D-4CEB-BAA5-ABE1433A93CCQ34037621-C4FED387-7E00-4041-9044-5A9552E4F824Q34393230-CC86C89B-5D09-4E44-A094-C720456E5351Q34647152-F76200E0-9657-4C2E-9A05-1284CC84A4CDQ35050218-A3DB3AFC-AEBD-4682-82EA-E84A4482C498Q35681898-379B730A-CF2D-482D-B821-8A4EC2BEDA48Q36046940-CEFB0ACB-AF93-4607-9A5E-370111C5B48BQ36667983-BF40015C-B7D1-49CF-95CC-CFAF25DD5CB1Q37115101-6DEAD360-1843-4612-A120-BE33AC0EE12CQ37506514-8E358940-3AD1-4A91-8A30-A3E0E795AB79Q37827385-E142445F-6DE0-43D0-BDBC-CCA3291DC7CAQ38320289-F7CBF093-07B8-4E04-BC87-F1FCBE287444Q38432422-22389A0F-C3AC-41CB-8E37-E98893D39556Q38618608-C5EBBBF0-3596-403D-AB41-778D40491D65Q39130169-C11FCCD3-43B9-4A86-84DE-7B9221CBE28FQ42476048-DB02F566-EB54-4287-846A-ACC7E094F008Q47446448-2C4AB7D0-F8CC-4D45-BCFA-519DAB031D77Q47769889-36A9DF9D-F9DA-4C05-B6AE-08C348E494AFQ48042923-3F472AE3-7ED1-456C-87F5-37A43219CFE0Q48870387-B89DB3AF-9A19-4E31-9776-6752510D8AB0Q50017647-10228A93-8533-41BB-9B93-447635C0E9D9Q54977584-E7CF757E-1E73-4126-A27D-E8CC4B24493DQ57040383-AFC61F52-BDE9-4A7C-B7CB-3AA2A5CD1867Q58763167-8B9E9600-84DA-42C8-9445-8B1307944676
P2860
Relationship between various clinical outcome assessments in patients with blepharospasm.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Relationship between various clinical outcome assessments in patients with blepharospasm.
@en
Relationship between various clinical outcome assessments in patients with blepharospasm.
@nl
type
label
Relationship between various clinical outcome assessments in patients with blepharospasm.
@en
Relationship between various clinical outcome assessments in patients with blepharospasm.
@nl
prefLabel
Relationship between various clinical outcome assessments in patients with blepharospasm.
@en
Relationship between various clinical outcome assessments in patients with blepharospasm.
@nl
P2093
P2860
P356
P1433
P1476
Relationship between various clinical outcome assessments in patients with blepharospasm.
@en
P2093
Christopher Kenney
George Comes
Roman Goertelmeyer
Susanne Grafe
P2860
P304
P356
10.1002/MDS.22368
P407
P577
2009-02-01T00:00:00Z